GeNO LLC Receives New Patent for Nitric Oxide Delivery Technology

Company now has ten issued US patents

Jan 31, 2012, 09:19 ET from GeNO LLC


COCOA, Fla., Jan. 31, 2012 /PRNewswire/ -- GeNO LLC (, a privately held, advanced development-stage technology company, today announced it has been awarded one new US patent for its proprietary Nitric Oxide generation and delivery technology. This patent brings the company's total issued US patents to ten.

GeNO's tenth patent (8,083,997) on NITROSYL (nitric oxide) for inhalation concerns the conversion of nitrogen dioxide (NO2) to nitric oxide (NO) using the GeNO cartridge technology.   "We continue to build on our company's strong intellectual property and invest in our unique, proprietary technology for nitric oxide generation and delivery," said GeNO LLC Founder and President Dr. David Fine. "This is another step towards what we hope will be a great improvement in patient treatment with inhaled nitric oxide." 

NITROSYL™ could add valuable options for clinicians treating a range of serious pulmonary and cardiac diseases with inhaled nitric oxide. GeNO's plans for both in-hospital and ambulatory inhaled nitric oxide systems would help address the cost, complexity and lack of portability of current treatment regimens, and would potentially reach a much larger group of patients. At present, GeNO's delivery technologies are investigational and are not approved by regulatory authorities.

GeNO is currently performing two Phase 2 trials: one, as a Pilot Study in Pulmonary Arterial Hypertension (PAH) and a second dose-escalation trial for the Treatment of Pulmonary Hypertension in patients with PAH and Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis (PH-IPF). Additional study details can be found on -- Identifiers NCT01092559 and NCT01265888. 

ABOUT GENO LLC                                        
GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and in-home use for potential chronic treatment. GeNO's NITROSYL Systems will be regulated by the FDA as new drugs with their own NDAs. These systems have been designated as Combination Products by the FDA Office of Combination Products, with the Division of Cardiovascular and Renal Products designated as the lead reviewer for GeNO's initial INDs.


Media Contacts:

Carla Burigatto, 610-457-2178                                              

Brian Heffron, 781-799-9568